GSK Plc (GSK)
47.03
-0.15
(-0.32%)
USD |
NYSE |
Oct 02, 16:00
47.02
-0.01
(-0.02%)
Pre-Market: 20:00
GSK Enterprise Value : 114.59B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 114.59B |
| October 01, 2026 | 114.89B |
| September 30, 2026 | 116.90B |
| September 29, 2026 | 119.28B |
| September 28, 2026 | 119.99B |
| September 25, 2026 | 119.06B |
| September 24, 2026 | 119.89B |
| September 23, 2026 | 120.01B |
| September 22, 2026 | 122.05B |
| September 21, 2026 | 122.78B |
| September 18, 2026 | 121.04B |
| September 17, 2026 | 122.74B |
| September 16, 2026 | 121.18B |
| September 15, 2026 | 120.62B |
| September 14, 2026 | 120.70B |
| September 11, 2026 | 116.82B |
| September 10, 2026 | 116.79B |
| September 09, 2026 | 117.83B |
| September 08, 2026 | 117.64B |
| September 04, 2026 | 120.38B |
| September 03, 2026 | 122.36B |
| September 02, 2026 | 121.49B |
| September 01, 2026 | 121.93B |
| August 31, 2026 | 121.10B |
| August 28, 2026 | 122.26B |
| Date | Value |
|---|---|
| August 27, 2026 | 121.14B |
| August 26, 2026 | 123.49B |
| August 25, 2026 | 124.78B |
| August 24, 2026 | 124.20B |
| August 21, 2026 | 125.47B |
| August 20, 2026 | 124.56B |
| August 19, 2026 | 126.42B |
| August 18, 2026 | 122.92B |
| August 17, 2026 | 121.16B |
| August 14, 2026 | 119.63B |
| August 13, 2026 | 121.51B |
| August 12, 2026 | 121.20B |
| August 11, 2026 | 122.42B |
| August 10, 2026 | 124.97B |
| August 07, 2026 | 126.58B |
| August 06, 2026 | 124.99B |
| August 05, 2026 | 123.55B |
| August 04, 2026 | 123.69B |
| August 03, 2026 | 123.65B |
| July 31, 2026 | 124.02B |
| July 30, 2026 | 124.78B |
| July 29, 2026 | 127.11B |
| July 28, 2026 | 128.10B |
| July 27, 2026 | 124.60B |
| July 24, 2026 | 123.33B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 512.95B |
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| Novo Nordisk A/S | 139.42B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 742.26M |
| Revenue (Quarterly) | 11.29B |
| Total Expenses (Quarterly) | 10.70B |
| EPS Diluted (Quarterly) | 0.2875 |
| Gross Profit Margin (Quarterly) | 75.05% |
| Profit Margin (Quarterly) | 6.58% |
| Earnings Yield | 6.75% |
| Operating Earnings Yield | 11.61% |
| Normalized Earnings Yield | 9.806 |